以预测治疗反应性的生物标记物
开启抗癌药的新时代
伟迈可生物有限公司(Wellmarker Bio Co. Ltd.)励志于通过预测治疗反应性的
生物标记物研发创新药,以能够实现免于对癌症的恐惧的世界。
伟迈可生物有限公司(Wellmarker Bio Co. Ltd.)励志于通过预测治疗反应性的
生物标记物研发创新药,以能够实现免于对癌症的恐惧的世界。
我们伟迈可研发可以预先推测患者疗效的
预测治疗反应性的生物标记物。
基于此,可以缩短研发创新药的时间以及相关成本,
并且可提高创新药研发的成功率。
In an interview with the Korean Economic Daily, CEO of Wellmarker Bio (Dong-Hoon Jin) said its targeted anti-cancer drug WM-S1-030 has receive...
2021-03-05Wellmarker Bio announced that on February 23, 2021 the company received approval from the Australian Therapeutic Goods Administration (TGA) fo...
2021-03-03Wellmarker Bio introduced Medidata’s Rave Study Feasibility and Rave EDC solution for its lead asset WM-S1(Colon cancer treatment)’s globa...
2021-01-26